Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Apr 6;25(4):628-630.
doi: 10.1093/neuonc/noad005.

Spotlighting cellular therapies to advance the treatment of medulloblastoma

Affiliations
Editorial

Spotlighting cellular therapies to advance the treatment of medulloblastoma

John A Ligon et al. Neuro Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

E.J.S. has pending patents related to vaccine technologies discussed in this editorial.

Figures

Figure 1.
Figure 1.
Development status for medulloblastoma cellular immunotherapy, as discussed in Schakelaar et al. ALT, adoptive lymphocyte transfer; DC, dendritic cell; Haplo, haploidentical; HCT, hematopoietic cell transplant; ttRNA, total tumor RNA. Images created with Biorender.com.

Comment on

  • Cellular immunotherapy for medulloblastoma.
    Schakelaar MY, Monnikhof M, Crnko S, Pijnappel EW, Meeldijk J, Ten Broeke T, Bovenschen N. Schakelaar MY, et al. Neuro Oncol. 2023 Apr 6;25(4):617-627. doi: 10.1093/neuonc/noac236. Neuro Oncol. 2023. PMID: 36219688 Free PMC article. Review.

References

    1. Juraschka K, Taylor MD. Medulloblastoma in the age of molecular subgroups: a review. J Neurosurg Pediatr. 2019;24(4):353–363. - PubMed
    1. Thompson EM, Hielscher T, Bouffet E, et al. . Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncol. 2016;17(4):484–495. - PMC - PubMed
    1. Baroni LV, Sampor C, Gonzalez A, et al. . Bridging the treatment gap in infant medulloblastoma: molecularly informed outcomes of a globally feasible regimen. Neuro Oncol. 2020;22(12):1873–1881. - PMC - PubMed
    1. Ligon JA, Wessel KM, Shah NN, Glod J. Adoptive cell therapy in pediatric and young adult solid tumors: current status and future directions. Front Immunol. 2022;13:846346. - PMC - PubMed
    1. Hwang EI, Sayour EJ, Flores CT, et al. . The current landscape of immunotherapy for pediatric brain tumors. Nat Cancer. 2022;3(1):11–24. - PubMed